# NCT03269136 (NCT03269136)

> PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03269136
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Pfizer
- Conditions: Multiple Myeloma
- Interventions: PF-06863135 monotherapy IV or SC; PF-06863135 + dexamethasone; PF-06863135 + lenalidomide; PF-06863135 + pomalidomide
- Enrollment: 101
- Primary outcome: Part 1: Number of Participants With Drug Limiting Toxicities (DLTs) Graded According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version (v)4.03
- Primary outcome: Part 2: Objective Response Rate (ORR) as Per International Myeloma Working Group (IMWG) Criteria
- Primary outcome: Part 2: Duration of Response (DOR) as Per IMWG Criteria

## Commentary we found

- YouTube: 4
- X threads: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03269136